Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]

NCT03767348 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.

NCT NCT03767348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03767348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Lead sponsor
Replimune, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 20, 2017
Completion date
December 31, 2028
Enrollment
340 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, microsatellite instability-high (msi-h), non-melanoma skin cancer (nmsc), non-small cell lung cancer (nsclc)